Correlation between genotype and sirolimus efficacy.
SOMATIC MUTATION
In an exploratory way, genetic testing was planned to be performed in all patients for whom tissue samples were available. Genetic results were procured for 52 patients (A sustained benefit of sirolimus was observed in 84% of Among the 61 patients who completed the 2-year treatment, a somatic mutation was known for 30 (49%); mutations were in 